Navigation Links
Coronary Artery Disease ARISE Trial Showed AGI-1067 Did Not Meet,Primary Endpoint

LONDON, March 19, 2007-AstraZeneca today announced that its collaboration partner AtheroGenics, Inc. (Nasdaq: AGIX) revealed first results from the ARISE (Aggressive Reduction of Inflammation Stops Events) phase III clinical outcomes trial which studied AGI-1067, an investigational anti-atherosclerotic agent with antioxidant and anti-inflammatory effects, in patients with coronary artery disease (CAD).
The ARISE trial did not meet its primary endpoint of a statistically significant relative risk reduction in a composite cardiovascular endpoint of CV death, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal stroke, use of coronary revascularisation and for angina pectoris with objective evidence of ischemia.

AstraZeneca and AtheroGenics will now work together to fully analyse the full data set for AGI-1067, including these first results. After completion of the final analysis, under the terms of the licence and collaboration agreement AstraZeneca has a 45-day period in which to decide whether or not to continue with the collaboration.

-Ends-
19 March 2007

Media enquiries:
Patricia O’Connor, Tel: +46 708 46 76 33
Edel McCaffrey, Tel: +44 (0) 207 304 5034
Steve Brown, Tel: +44 (0) 207 304 5033

Investor Relations:
Mina Blair, Tel: +44 (0) 207 304 5084
Jonathan Hunt, Tel: +44 (0) 207 304 5087
Jörgen Winroth, Tel: +1 (212) 579 0506
Ed Seage, Tel: +1 302 886 4065
Notes To Editors
The ARISE study
ARISE was a double-blind, randomised, placebo controlled study which involved more than 6,000 patients with coronary artery disease from over 250 centres in Canada, South Africa, the UK and the US. The study was designed to evaluate the additional benefits of adding AGI-1067 to current standard of care therapies, on several outcomes due to coronary vascular events such as death, heart attack, str
'"/>




Page: 1 2

Related medicine technology :

1. New Point-of-Care Methods to Measure Coronary and Cerebrovascular Risk
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
5. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
6. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
9. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
10. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems
11. Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
Post Your Comments:
(Date:3/27/2015)... Zimmer Holdings, Inc. (NYSE and SIX: ZMH) is ... patients. Available in both small (6mm) and ... Fixation System from Zimmer is a modular system that offers ... XtraFix System allows surgeons to eliminate steps, as ... resulting in saved time, costs and overall team effort. ...
(Date:3/27/2015)... DALLAS , March 27, 2015 ... Market by Product (Diagnostic Catheter (Conventional, Advanced, Ultrasound), Ablation ... ICE, X-ray)) & Indication (AF, VT, WPW) - Global ... Market is expected to reach around ~$4.73 Billion by ... forecast period 2014 to 2019. Browse ...
(Date:3/27/2015)... 2015  Johnson & Johnson (NYSE: JNJ ) will ... Time) on Thursday, April 23, 2015, from the State Theatre ... Investors and other interested parties may access the live audio ... www.jnj.com and clicking on the webcast icon. ... made available a few hours after the live meeting concludes. ...
Breaking Medicine Technology:Zimmer Debuts New Modular External Fixation System 2Zimmer Debuts New Modular External Fixation System 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4
... in Cellular and Molecular Medicine at Boston Children,s Hospital ... developed a molecular delivery platform that overcomes one of the ... cancer: Making sure the treatment gets to the right place ... PhD, of the PCMM/IDI, and a former fellow from her ...
... 18, 2012  Genetic testing to determine a more accurate initial ... remains rare, but is often done for inappropriate patients, according ... pharmacy benefit manager (PBM). The study will be presented on ... (AMCP),s 24th Annual Meeting & Expo in San Francisco. ...
Cached Medicine Technology:Packaging therapeutic RNAs for targeted treatment of breast cancer 2Packaging therapeutic RNAs for targeted treatment of breast cancer 3Packaging therapeutic RNAs for targeted treatment of breast cancer 4Genetic testing for new warfarin patients is rare, but often inappropriate 2
(Date:3/28/2015)... Coffee could not only perk you up in the morning ... have found. , They found that those who drank coffee ... fight gum disease. Does coffee, then, help fight gum disease? ... Goldman School of Dental Medicine explored in a study ... of Periodontology. , “This is the first long-term study of ...
(Date:3/28/2015)... 2015 "Necrorun" was featured on NewsWatch ... look at the latest and coolest applications on the ... host of NewsWatch and technology expert, conducted the app ... entertaining endless runner game with knights, nature, and peasants. ... in 2009, according to Eurogamer. The popularity of these ...
(Date:3/28/2015)... With more than 4,500 scientists, ... osteoporosis, osteoarthritis and musculoskeletal diseases gathered here for ... the first time in the 17-year history of ... hot-button topic is an emerging non-pharmaceutical protocol for ... principles of Wolff’s law, osteogenic loading at multiples ...
(Date:3/28/2015)... The California-based leading wig brand UniWigs ... shopping on UniWigs during the Easter Holidays from today ... promotion on April Fools’ Day. , As the winter ... the corner. Easter Festival, with religious origins to countries ... holiday after Christmas. The best wig provider, UniWigs, would ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 India ... coverage is made available to all visitors who purchase ... immediately. All members are encouraged to purchase the insurance ... avoid lack of proper coverage for pre-existing medical conditions. ... one or two medical conditions with serious consequences to ...
Breaking Medicine News(10 mins):Health News:New Research Impliments Coffee May Help Fight Gum Disease and Increasing Benefits With Tylers Coffee 2Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3
... ... Discovery Health, - PREGNANT MAN Premieres Tuesday, November 18, at ... November 19, at 10:00 PM ET/PT -, SILVER SPRING, Md., Nov. ... Thomas Beatie tells the definitive story of,his first pregnancy this Tuesday on ...
... DALLAS, Nov. 13 As Sandy Mullen and ... they were,caring for in the eating disorders unit ... the seemingly successful treatment of a,patient,s primary addiction ... After reviewing hundreds of cases, Mullen, RN, an ...
... 13 Nile Therapeutics,Inc. (Nasdaq: NLTX ), a ... cardiovascular disease, today announced financial results,for the three and ... loss for the three months ended September 30, 2008 ... million, or $0.35 per,share, for the same period of ...
... learned might one day lead to vaccine that works , , ... develop an AIDS vaccine has failed, but researchers report that ... one more effective. , "It,s raised a whole new set ... answer to get us to a successful vaccine," said Dr. ...
... Corp. (Nasdaq:,HMSY) today announced that it will present at ... November 18-19, 2008 at The New,York Palace Hotel., ... at 11:00 am,ET., HMS Holdings Corp. (Nasdaq: ... and program integrity services for government,healthcare programs. The company,s ...
... N.J., Nov. 13 Medco Health,Solutions, Inc. (NYSE: ... Jr., and other members of the Medco senior leadership ... financial results and,business outlook to analysts and investors during ... titled "Inventing World-Class Healthcare,Solutions," is scheduled to begin at ...
Cached Medicine News:Health News:Pregnant Man Thomas Beatie Is Pregnant Again 2Health News:Pregnant Man Thomas Beatie Is Pregnant Again 3Health News:Dallas Addiction Specialists Reveal Discovery in New Book 2Health News:Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results 2Health News:Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results 3Health News:Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results 4Health News:Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results 5Health News:HIV Vaccine Failure Still Brings Insights 2Health News:Medco to Webcast 2008 Analyst Day Conference 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: